Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 17;6(9):e1323619. doi: 10.1080/2162402X.2017.1323619

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 3. — Kaplan–Meier analysis of PFS and OS with different platinum sensitivity and treatments (A and B) Kaplan–Meier survival curves of progression-free survival (A) and overall survival (B) for the platinum-resistant/refractory patients and platinum-sensitive patients, using the log-rank test to evaluate significance. (C and D) Kaplan–Meier survival curves of progression-free survival (C) and overall survival (D) in platinum-resistant/refractory patients based on different treatments (DTC or DTC+CIK treatment), using the log-rank test to evaluate significance. (E and F) Kaplan–Meier survival curves of progression-free survival (E) and overall survival (F) in disease measurable platinum-resistant/refractory patients based on different treatments (DTC or DTC+CIK treatment), using the log-rank test to evaluate significance. (G and H) Kaplan–Meier survival curves of progression-free survival (G) and overall survival (H) in disease controlled patients based on the number of cycles of DAC treatment, using the log-rank test to evaluate significance. PFS, progression-free survival. OS, overall survival.